Current cancer models often fail to replicate tumor biology, resulting in poor drug predictability and high clinical trial failure rates.
Carcinotech addresses these challenges with advanced, precisely engineered models that closely mimic the phenotypic characteristics of in vivo tumors. Our models are highly reproducible and provide clinically predictive insights to better bridge the gap between research and successful clinical outcomes.
Tumor Organoids(Dissociated Tissue Derived Models) |
Carcino3D™ Tumor |
PDX Models(Humanized Mice Models with Orthotopic Engraftment) |
|
|---|---|---|---|
| TME Complexity | Low to moderate | High | High |
| Tumor Infiltrating Immune Cells |
|
|
|
| Tumor Heterogeneity | Low | High | High |
| Uniformity Across Individual Models |
|
|
|
| Model Development Time | 12 weeks | 6-12 weeks | 12-24 weeks |
| Stromal cells present |
|
|
|
| Cost | Low | Moderate | High |
| Ethical |
|
|
|
Our robust models are invaluable tools for both early drug discovery and preclinical efficacy testing.
